{"protocolSection": {"identificationModule": {"nctId": "NCT01343407", "orgStudyIdInfo": {"id": "1029-003"}, "secondaryIdInfos": [{"id": "2010-022391-31", "type": "EUDRACT_NUMBER"}, {"id": "MK-1029-003", "type": "OTHER", "domain": "Merck Protocol Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)", "officialTitle": "A Two-Part, Multicenter, Randomized, Clinical Trial to Study the Effects of Multiple Doses of MK-1029 on the Late Asthmatic Response to Lung Allergen Challenge in Asthmatics"}, "statusModule": {"statusVerifiedDate": "2019-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-04-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2012-01-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-01-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-04-26", "studyFirstSubmitQcDate": "2011-04-26", "studyFirstPostDateStruct": {"date": "2011-04-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-02", "resultsFirstSubmitQcDate": "2019-02-06", "resultsFirstPostDateStruct": {"date": "2019-02-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-02-13", "lastUpdatePostDateStruct": {"date": "2019-03-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This was a 2-part study in participants with allergen-induced asthma. It included a procedural pilot component (Part 1). Part 1 tested the key procedures and timing of Part 2; no study drug was administered during Part 1. Part 2 included a pre-randomization placebo run-in (Period 1) and 3 treatment periods (Periods 2, 3, and 4) during which participants were randomized to receive double-blind placebo, MK-1029 60 mg or MK-1029 500 mg in a crossover design. The treatment periods were followed by a minimum 21-day washout. Part 2 assessed allergen-induced sputum eosinophils and allergen-induced late asthmatic response (LAR) compared to placebo."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 16, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-1029 60 mg", "type": "EXPERIMENTAL", "description": "Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design", "interventionNames": ["Drug: MK-1029 10 mg", "Drug: Placebo for MK-1029 10 mg"]}, {"label": "MK-1029 500 mg", "type": "EXPERIMENTAL", "description": "Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design", "interventionNames": ["Drug: MK-1029 100 mg", "Drug: Placebo for MK-1029 100 mg"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Part II - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design", "interventionNames": ["Drug: Placebo for MK-1029 10 mg", "Drug: Placebo for MK-1029 100 mg"]}], "interventions": [{"type": "DRUG", "name": "MK-1029 10 mg", "description": "Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design", "armGroupLabels": ["MK-1029 60 mg"]}, {"type": "DRUG", "name": "MK-1029 100 mg", "description": "Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design", "armGroupLabels": ["MK-1029 500 mg"]}, {"type": "DRUG", "name": "Placebo for MK-1029 10 mg", "description": "Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design.\"", "armGroupLabels": ["MK-1029 60 mg", "Placebo"]}, {"type": "DRUG", "name": "Placebo for MK-1029 100 mg", "description": "Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design", "armGroupLabels": ["MK-1029 500 mg", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent Change From Baseline in Percent (%) Eosinophils in Induced Sputum At 8 Hours Post Allergen", "description": "The effect of MK-1029 on the reduction of percent (%) sputum eosinophils following allergen challenge with standardized cat pelt or hair (CPH) allergen extract was assessed. Baseline % eosinophils were measured before treatment (and pre-allergen challenge) on Day -1. The change from baseline in allergen-induced % sputum eosinophils at 8 hr post allergen challenge testing on Day 5 was analyzed using a repeated measures linear mixed effects model with treatment, period, time, time-by-treatment interaction as fixed factors, and participant as a random factor. Outcome Measure 6 shows % eosinophil values at baseline.", "timeFrame": "Baseline (Day -1) and Day 5 (8 hours after allergen challenge in each treatment period)"}, {"measure": "Forced Expiratory Volume in One Second (FEV1) From 3 to 8 Hours Postdose (AUC3-8hr) During the Late Asthmatic Response (LAR)", "description": "The effect of MK-1029 on the FEV1 AUC(3-8hr) during LAR was assessed. The unit of measure for an FEV1 AUC value is L\\*hr. The effect of treatment on LAR was assessed as the percent-fall in FEV1 AUC(3-8hr), evaluated by spirometry following allergen challenge on Day 5. The FEV1 AUC(3-8hr) during LAR was analyzed using a linear mixed effects model with treatment and period as fixed factors and participant as a random factor.", "timeFrame": "From 3 to 8 hours after allergen challenge on Day 5 of each treatment period"}, {"measure": "Number of Participants With an Adverse Event (AE)", "description": "The number of participants who had at least one adverse event (AE) during study treatment and follow-up was assessed. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.", "timeFrame": "Up to 26 days in each treatment period"}, {"measure": "Number of Participants Discontinuing Treatment Due to an AE", "description": "The number of participants who discontinued study treatment due to an AE was assessed. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.", "timeFrame": "Up to 5 days in each treatment period"}], "secondaryOutcomes": [{"measure": "Percent Inhibition of the Expression of Cluster of Differentiation (CD)11b on Blood Eosinophils", "description": "The concentration of CD11b in whole blood samples was assessed. The percent-inhibition of CD11b (a cell-surface biomarker on activated eosinophils) was assessed following inhaled allergen challenge on Day 5. Inhibition of CD11b expression was assessed by analyzing the % inhibition of CD11b expression from baseline (Day -1) using a linear mixed-effects model with period, treatment, time, and treatment by time as fixed terms and subject as a random term. Outcome Measure 7 shows CD11b expression values at baseline.", "timeFrame": "Baseline (Day -1, predose), 24 hours after allergen challenge on Day 5 in each treatment period"}], "otherOutcomes": [{"measure": "Baseline (Pre-Treatment) Percent (%) Eosinophils", "description": "Baseline values of the percent (%) sputum eosinophils were measured pre-antigen challenge on Day -1. The baseline % eosinophil values were provided to assess the change from baseline after treatment.", "timeFrame": "Baseline (Day -1), pre-antigen challenge"}, {"measure": "Baseline Expression of Cluster of Differentiation (CD)11b on Blood Eosinophils", "description": "Baseline values for the antibody-specific expression of CD11b in whole blood samples, as obtained by flow cytometry, were obtained. The baseline CD11b values were obtained before treatment with MK-1029 60 mg, MK-1029 500 mg, or placebo, and were used to assess the effects of treatment.", "timeFrame": "Day 1, predose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nParts 1 and 2\n\n* Is male or a female of non-childbearing potential\n* Has a history of allergen-induced asthma for at least 6 months\n* Is judged to be in good health (other than asthma)\n* Is able to perform reproducible pulmonary function testing\n* Has a positive methacholine challenge test on Day -1\n* Has an allergic response to house dust mite allergen as defined by positive skin prick test\n* Is a nonsmoker and/ or has not used nicotine or nicotine-containing products for at least 12 months\n* Has body mass index (BMI) \u226517 kg/m\\^2, but \u226433 kg/m\\^2\n\nPart 2 only\n\n* Must demonstrate a dual airway response to an allergen challenge in Period 1, decrease in FEV1 of at least 20% 0 to 2 hours after allergen challenge for early asthmatic response (EAR) and a positive late asthmatic response (LAR) to an inhaled allergen challenge as defined by a bronchoconstrictive response of at least 15% reduction in FEV1 3 to 8 hours after allergen challenge\n* Can tolerate sputum induction and produce adequate sputum\n\nExclusion Criteria:\n\nParts 1 and 2\n\n* Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses additional risk to the participant\n* Has recent (4 weeks) or ongoing upper or lower respiratory tract infection\n* Is unable to refrain from or anticipates the use of any medication other than the ones permitted in this study\n* Has taken oral, intramuscular, intra-articular, high-potency topical or orally inhaled corticosteroids within 8 weeks\n* Has taken the following medications outside the washout margins: nasal corticosteroids and anti-leukotrienes within 3 weeks; inhaled long-acting \u03b22-agonists, long-acting antihistamines (e.g., loratadine, sustained-release agents), intra-nasal anticholinergics over-the-counter decongestants within 1 week; short-acting oral decongestants, short-acting antihistamines (e.g., chlorpheniramine) within 48 hours\n* Consumes excessive amounts of alcohol or caffeinated beverages\n* Has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 3 months\n* Has a history of severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food\n* Is a nursing mother\n* Has a history of receiving anti-immunoglobulin E (IgE) or immunotherapy\n* Has a history of serious allergies to drugs or a history of hypersensitivity to mometasone furoate or any of its inactive ingredients such as lactose, or inhaled salbutamol, antihistamines, or any\n\nother potential asthma/anaphylaxis rescue medication\n\nPart 2 only\n\n- Has a decline in FEV1 of 70% or greater from the post allergen diluent baseline and/or FEV1 \\<1.0L or has symptomatic drop in FEV1 associated with shortness of breath unresolved with bronchodilators within a reasonable timeframe (60 minutes) after the allergen challenge study in Period 1", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This was a 2-part study. Part 1 was a procedural pilot, performed first and including placebo run-in (Period 1), with no study drug administration. Part 2 began with pre-randomization placebo run-in (Period 1), followed by 3 randomized, crossover treatment periods (Periods 2, 3, and 4). The Participant Flow applies only to randomized participants.", "groups": [{"id": "FG000", "title": "Sequence 1", "description": "Placebo\u2192MK-1029 60 mg\u2192 MK-1029 500 mg. Participants received 5 days of crossover treatment (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods."}, {"id": "FG001", "title": "Sequence 2", "description": "MK-1029 60 mg\u2192MK-1029 500 mg\u2192Placebo. Participants received 5 days of crossover treatment (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods."}, {"id": "FG002", "title": "Sequence 3", "description": "MK-1029 500 mg\u2192Placebo\u2192 MK-1029 60 mg. Participants received 5 days of crossover treatment (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods."}, {"id": "FG003", "title": "Sequence 4", "description": "Placebo\u2192MK-1029 500 mg\u2192 MK-1029 60 mg. Participants received 5 days of crossover treatment (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods."}, {"id": "FG004", "title": "Sequence 5", "description": "MK-1029 500 mg\u2192MK-1029 60 mg\u2192Placebo. Participants received 5 days of crossover treatment (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods."}, {"id": "FG005", "title": "Sequence 6", "description": "MK-1029 60 mg\u2192Placebo\u2192 MK-1029 500 mg. Participants received 5 days of crossover treatment (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods."}], "periods": [{"title": "First Treatment Period (Part 2)", "milestones": [{"type": "STARTED", "comment": "Allergen challenge was done 1 hour after dosing on Day 5 of each treatment period.", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "First Washout (Part 2)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Second Treatment Period (Part 2)", "milestones": [{"type": "STARTED", "comment": "Allergen challenge was done 1 hour after dosing on Day 5 of each treatment period.", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Second Washout (Part 2)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Third Treatment Period (Part 2)", "milestones": [{"type": "STARTED", "comment": "Allergen challenge was done 1 hour after dosing on Day 5 of each treatment period.", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Randomized Participants", "description": "Crossover treatment with MK-1029 60 mg, MK-1029 500 mg, and matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.3", "spread": "7.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent Change From Baseline in Percent (%) Eosinophils in Induced Sputum At 8 Hours Post Allergen", "description": "The effect of MK-1029 on the reduction of percent (%) sputum eosinophils following allergen challenge with standardized cat pelt or hair (CPH) allergen extract was assessed. Baseline % eosinophils were measured before treatment (and pre-allergen challenge) on Day -1. The change from baseline in allergen-induced % sputum eosinophils at 8 hr post allergen challenge testing on Day 5 was analyzed using a repeated measures linear mixed effects model with treatment, period, time, time-by-treatment interaction as fixed factors, and participant as a random factor. Outcome Measure 6 shows % eosinophil values at baseline.", "populationDescription": "Participants who comply with the protocol sufficiently to ensure data obtained will be likely to exhibit the effects of treatment, according to the underlying scientific model.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline (Day -1) and Day 5 (8 hours after allergen challenge in each treatment period)", "groups": [{"id": "OG000", "title": "MK-1029 60 mg", "description": "Participants received 5 days of treatment with MK-1029 60 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG001", "title": "MK-1029 500 mg", "description": "Participants received 5 days of treatment with MK-1029 500 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG002", "title": "Placebo", "description": "Participants received 5 days of treatment with placebo (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.6", "lowerLimit": "-22.5", "upperLimit": "1.3"}, {"groupId": "OG001", "value": "-7.3", "lowerLimit": "-18.3", "upperLimit": "3.6"}, {"groupId": "OG002", "value": "11.6", "lowerLimit": "-1.0", "upperLimit": "24.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.011", "statisticalMethod": "Linear mixed effects model", "paramType": "Difference in Least Squares Means (LSM)", "paramValue": "-22.2", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-35.7", "ciUpperLimit": "-8.7"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.023", "statisticalMethod": "Linear mixed effects model", "paramType": "Difference in LSM", "paramValue": "-18.9", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.1", "ciUpperLimit": "-5.8"}]}, {"type": "PRIMARY", "title": "Forced Expiratory Volume in One Second (FEV1) From 3 to 8 Hours Postdose (AUC3-8hr) During the Late Asthmatic Response (LAR)", "description": "The effect of MK-1029 on the FEV1 AUC(3-8hr) during LAR was assessed. The unit of measure for an FEV1 AUC value is L\\*hr. The effect of treatment on LAR was assessed as the percent-fall in FEV1 AUC(3-8hr), evaluated by spirometry following allergen challenge on Day 5. The FEV1 AUC(3-8hr) during LAR was analyzed using a linear mixed effects model with treatment and period as fixed factors and participant as a random factor.", "populationDescription": "Participants who comply with the protocol sufficiently to ensure data obtained will be likely to exhibit the effects of treatment, according to the underlying scientific model.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L*hr", "timeFrame": "From 3 to 8 hours after allergen challenge on Day 5 of each treatment period", "groups": [{"id": "OG000", "title": "MK-1029 60 mg", "description": "Participants received 5 days of treatment with MK-1029 60 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG001", "title": "MK-1029 500 mg", "description": "Participants received 5 days of treatment with MK-1029 500 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG002", "title": "Placebo", "description": "Participants received 5 days of treatment with placebo (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41.24", "lowerLimit": "18.16", "upperLimit": "93.66"}, {"groupId": "OG001", "value": "49.76", "lowerLimit": "31.02", "upperLimit": "79.83"}, {"groupId": "OG002", "value": "86.37", "lowerLimit": "55.79", "upperLimit": "133.70"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.006", "statisticalMethod": "Linear mixed effects model", "paramType": "LS Mean Ratio (LSMR)", "paramValue": "0.48", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.32", "ciUpperLimit": "0.72", "otherAnalysisDescription": "% Inhibition: 52.2 (90% CI: 28.3, 68.2). The % Inhibition of FEV1\\*hr (reduction of the allergen-induced LAR) for MK-1029 vs Placebo was calculated as 100\\*(1-LSMR)."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.012", "statisticalMethod": "Linear mixed effects model", "paramType": "LS Mean Ratio (LSMR)", "paramValue": "0.58", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.41", "ciUpperLimit": "0.81", "otherAnalysisDescription": "% Inhibition: 42.4 (90% CI: 19.3, 58.8) The % Inhibition of FEV1\\*hr (reduction of the allergen-induced LAR) for MK-1029 vs Placebo was calculated as 100\\*(1-LSMR)."}]}, {"type": "SECONDARY", "title": "Percent Inhibition of the Expression of Cluster of Differentiation (CD)11b on Blood Eosinophils", "description": "The concentration of CD11b in whole blood samples was assessed. The percent-inhibition of CD11b (a cell-surface biomarker on activated eosinophils) was assessed following inhaled allergen challenge on Day 5. Inhibition of CD11b expression was assessed by analyzing the % inhibition of CD11b expression from baseline (Day -1) using a linear mixed-effects model with period, treatment, time, and treatment by time as fixed terms and subject as a random term. Outcome Measure 7 shows CD11b expression values at baseline.", "populationDescription": "Participants who comply with the protocol sufficiently to ensure data obtained will be likely to exhibit the effects of treatment, according to the underlying scientific model.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of inhibition", "timeFrame": "Baseline (Day -1, predose), 24 hours after allergen challenge on Day 5 in each treatment period", "groups": [{"id": "OG000", "title": "MK-1029 60 mg", "description": "Participants received 5 days of treatment with MK-1029 60 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG001", "title": "MK-1029 500 mg", "description": "Participants received 5 days of treatment with MK-1029 500 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG002", "title": "Placebo", "description": "Participants received 5 days of treatment with placebo (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "89.9", "lowerLimit": "71.8", "upperLimit": "108.0"}, {"groupId": "OG001", "value": "87.4", "lowerLimit": "71.2", "upperLimit": "103.5"}, {"groupId": "OG002", "value": "4.1", "lowerLimit": "-12.6", "upperLimit": "20.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "Linear mixed effects model", "paramType": "LSM Difference", "paramValue": "85.84", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "65.3", "ciUpperLimit": "106.4", "estimateComment": "Full inhibition is \u226574% inhibition of blood eosinophil CD11b expression at trough"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "Linear mixed effects model", "paramType": "LSM Difference", "paramValue": "83.29", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "63.9", "ciUpperLimit": "102.7", "estimateComment": "Full inhibition is \u226574% inhibition of blood eosinophil CD11b expression at trough"}]}, {"type": "PRIMARY", "title": "Number of Participants With an Adverse Event (AE)", "description": "The number of participants who had at least one adverse event (AE) during study treatment and follow-up was assessed. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.", "populationDescription": "All randomized participants who received at least one dose of study treatment and had follow-up.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 26 days in each treatment period", "groups": [{"id": "OG000", "title": "MK-1029 60 mg", "description": "Participants received 5 days of treatment with MK-1029 60 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG001", "title": "MK-1029 500 mg", "description": "Participants received 5 days of treatment with MK-1029 500 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG002", "title": "Placebo", "description": "Participants received 5 days of treatment with placebo (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "11"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Discontinuing Treatment Due to an AE", "description": "The number of participants who discontinued study treatment due to an AE was assessed. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 5 days in each treatment period", "groups": [{"id": "OG000", "title": "MK-1029 60 mg", "description": "Participants received 5 days of treatment with MK-1029 60 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG001", "title": "MK-1029 500 mg", "description": "Participants received 5 days of treatment with MK-1029 500 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG002", "title": "Placebo", "description": "Participants received 5 days of treatment with placebo (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Baseline (Pre-Treatment) Percent (%) Eosinophils", "description": "Baseline values of the percent (%) sputum eosinophils were measured pre-antigen challenge on Day -1. The baseline % eosinophil values were provided to assess the change from baseline after treatment.", "populationDescription": "Participants who were compliant with the protocol sufficiently to ensure their data would be likely to exhibit the effects of treatment were included.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "% sputum eosinophils", "timeFrame": "Baseline (Day -1), pre-antigen challenge", "groups": [{"id": "OG000", "title": "MK-1029 60 mg", "description": "Participants received 5 days of treatment with MK-1029 60 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG001", "title": "MK-1029 500 mg", "description": "Participants received 5 days of treatment with MK-1029 500 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG002", "title": "Placebo", "description": "Participants received 5 days of treatment with placebo (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.42", "lowerLimit": "0.47", "upperLimit": "80.56"}, {"groupId": "OG001", "value": "17.04", "lowerLimit": "0.66", "upperLimit": "78.22"}, {"groupId": "OG002", "value": "11.99", "lowerLimit": "0.48", "upperLimit": "23.40"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Baseline Expression of Cluster of Differentiation (CD)11b on Blood Eosinophils", "description": "Baseline values for the antibody-specific expression of CD11b in whole blood samples, as obtained by flow cytometry, were obtained. The baseline CD11b values were obtained before treatment with MK-1029 60 mg, MK-1029 500 mg, or placebo, and were used to assess the effects of treatment.", "populationDescription": "Participants who were compliant with the protocol sufficiently to ensure their data would be likely to exhibit the effects of treatment were included.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Antibody fluorescence units", "timeFrame": "Day 1, predose", "groups": [{"id": "OG000", "title": "MK-1029 60 mg", "description": "Participants received 5 days of treatment with MK-1029 60 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG001", "title": "MK-1029 500 mg", "description": "Participants received 5 days of treatment with MK-1029 500 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}, {"id": "OG002", "title": "Placebo", "description": "Participants received 5 days of treatment with placebo (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62619", "spread": "28790"}, {"groupId": "OG001", "value": "62254", "spread": "13690"}, {"groupId": "OG002", "value": "63398", "spread": "22022"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 26 days in each treatment period", "description": "One participant had an episode of respiratory distress (a serious AE) during the placebo run-in, and was not randomized to study treatment. The at-risk population for AEs is all participants who received study drug in a treatment period.", "eventGroups": [{"id": "EG000", "title": "60 mg MK-1029", "description": "Participants received 5 days of treatment with MK-1029 60 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods", "deathsNumAffected": 0, "deathsNumAtRisk": 14, "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 11, "otherNumAtRisk": 14}, {"id": "EG001", "title": "500 mg MK-1029", "description": "Participants received 5 days of treatment with MK-1029 500 mg (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods", "deathsNumAffected": 0, "deathsNumAtRisk": 16, "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 10, "otherNumAtRisk": 16}, {"id": "EG002", "title": "Placebo", "description": "Participants received 5 days of treatment with placebo (once-daily dosing) in 3 periods, followed by a minimum 21-day washout between treatment periods", "deathsNumAffected": 0, "deathsNumAtRisk": 16, "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 11, "otherNumAtRisk": 16}], "otherEvents": [{"term": "Gingival pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Catheter site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}]}, {"term": "Catheter site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 6, "numAffected": 3, "numAtRisk": 16}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Muscle strain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Tooth fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 7, "numAffected": 5, "numAtRisk": 16}]}, {"term": "Lethargy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Breast mass", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 10, "numAffected": 6, "numAtRisk": 16}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}]}, {"term": "Sputum increased", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "This study is intended for publication, even if terminated prematurely. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "New Zealand", "South Africa", "United Kingdom"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}